MicroRNA-21 guide and passenger strand regulation of adenylosuccinate lyase-mediated purine metabolism promotes transition to an EGFR-TKI-tolerant persister state

Wen Cai Zhang, Nicholas Skiados, Fareesa Aftab, Cerena Moreno, Luis Silva, Paul Joshua Anthony Corbilla, John M. Asara, Aaron N. Hata and Frank J. Slack

© The Author(s) 2022, corrected publication 2022

In EGFR-mutant lung cancer, drug-tolerant persister cells (DTPCs) show prolonged survival when receiving EGFR tyrosine kinase inhibitor (TKI) treatments. They are a likely source of drug resistance, but little is known about how these cells tolerate drugs. Ribonucleic acids (RNAs) molecules control cell growth and stress responses. Nucleic acid metabolism provides metabolites, such as purines, supporting RNA synthesis and downstream functions. Recently, noncoding RNAs (ncRNAs), such as microRNAs (miRNAs), have received attention due to their capacity to repress gene expression via inhibitory binding to downstream messenger RNAs (mRNAs). Here, our study links miRNA expression to purine metabolism and drug tolerance. MiR-21-5p (guide strand) is a commonly upregulated miRNA in disease states, including cancer and drug resistance. However, the expression and function of miR-21-3p (passenger strand) are not well understood. We found that upregulation of miR-21-5p and miR-21-3p tune purine metabolism leading to increased drug tolerance. Metabolomics data demonstrated that purine metabolism was the top pathway in the DTPCs compared with the parental cells. The changes in purine metabolites in the DTPCs were partially rescued by targeting miR-21.

Analysis of protein levels in the DTPCs showed that reduced expression of adenylosuccinate lyase (ADSL) was reversed after the miR-21 knockdown. ADSL is an essential enzyme in the de novo purine biosynthesis pathway by converting succino-5-aminoimidazole-4-carboxamide riboside (succino-AICAR or SAICAR) to AICAR (or acadesine) and adenylosuccinate to adenosine monophosphate (AMP). In the DTPCs, miR-21-5p and miR-21-3p repress ADSL expression. The levels of top decreased metabolite in the DTPCs, AICAR was reversed when miR-21 was blocked. AICAR induced oxidative stress, evidenced by increased reactive oxygen species (ROS) and reduced expression of nuclear factor erythroid-2-related factor 2 (NRF2). Concurrently, miR-21 knockdown induced ROS generation. Therapeutically, a combination of AICAR and osimertinib increased ROS levels and decreased osimertinib-induced NRF2 expression. In a MIR21 knockout mouse model, MIR21 loss-of-function led to increased purine metabolites but reduced ROS scavenging capacity in lung tissues in physiological conditions. Our data has established a link between ncRNAs, purine metabolism, and the redox imbalance pathway. This discovery will increase knowledge of the complexity of the regulatory RNA network and potentially enable novel therapeutic options for drug-resistant patients.

INTRODUCTION
Nucleic acids including deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) are macromolecules that are central to all biological functions [1]. Nucleic acid molecules consist of purine and pyrimidine nucleosides [2]. Purine and pyrimidine nucleic acids include adenosine (A), guanosine (G), as well as cytosine (C), thymine (T), and uracil (U). The process of purine nucleoside metabolism is mainly catalyzed by metabolic enzyme activities leading to the creation of adenosine monophosphate (AMP) [3]. For example, adenylosuccinate lyase (ADSL) is an essential enzyme involved in purine metabolism. It catalyzes two reactions in the de novo purine biosynthetic pathway: the conversion of succino-5-aminoimidazole-4-carboxamide riboside (succino-AICAR or SAICAR) to AICAR (or acadesine) and the conversion of adenylosuccinate (S-AMP) to AMP [4]. The metabolic enzymes mediating purine metabolism are finely controlled at the transcriptional or post-translational level [5]. For example, the mechanistic target of rapamycin complex 1 (mTORC1) regulates methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) enzyme at the transcriptional level contributing to purine synthesis [6]. However, it is not clear how the processes for purine metabolism are controlled after genetic transcription [7]. Thus, it is interesting to understand...
which molecules are involved in purine biosynthesis at the post-transcriptional level.

Small noncoding RNAs such as microRNAs (miRNAs) tune gene expression via regulating protein degradation and RNA stability [8, 9]. In miRNA biosynthesis, transcription generates a primary miRNA (pri-miRNA) that is subsequently processed to produce a precursor miRNA (pre-miRNA) that generates two potentially active miRNAs, the guide and passenger strand, or 5p and 3p strand [10]. Recently, miRNAs have received increased attention due to their modulating metabolic pathways [11, 12]. For example, a low oxygen-induced miRNA, miR-210 represses succinate dehydrogenase (SDH) complex subunit D expression leading to dysregulation of the tricarboxylic acid (TCA) cycle and electron transfer chain [13]. miR-147b regulates VHL and SDH complex in response to hypoxia [14]. Reduced miR-200c de-represses lactate dehydrogenase A resulting in increased lactate production and enhanced aerobic glycolysis [15]. Furthermore, miRNAs regulate nucleic acid synthesis. For instance, nuclear factor erythroid-2-related factor 2 (NRF2) activation-induced downregulation of miR-1 and miR-206 derepress glucose-6-phosphate dehydrogenase, phosphogluconate dehydrogenase, and transketolase. These enzymes increased nucleic acid synthesis by providing a ribose [16]. In addition, miRNA expression levels can distinguish various diseases, including cancer [17–19]. miRNAs can be used as therapeutic targets alone or combined with small molecules [20–25]. Given this precedence, it is critical to understand if miRNAs modulate purine synthesis and metabolism in a disease-dependent context.

Wild-type epidermal growth factor receptor (EGFR) is critical to maintaining normal cell growth and organ development [26]. Conversely, somatic EGFR mutations drive epithelial cell-derived tumors such as lung and other types of cancer [27, 28]. To block mutation-induced EGFR overactivation, EGFR tyrosine kinase inhibitors (TKIs) including gefitinib and erlotinib, have been applied clinically. By binding to the EGFR adenosine triphosphate (ATP) binding pocket, gefitinib/erlotinib blocks constitutive EGFR phosphorylation and its downstream phosphoinositide 3-kinase (PI3K)/AKT serine/threonine kinase (AKT) and RAS/extracellular signal-regulated kinase (ERK) signaling pathways [29]. However, about half of the acquired resistant cases to gefitinib are caused by an EGFR Thr790Met (T790M) mutation increasing the affinity for ATP [30]. Osimertinib, a 3rd generation of EGFR TKI, can overcome acquired T790M [31], and has also demonstrated superior activity as a first-line treatment for EGFR-mutant NSCLC with activating del19 and L858R mutation in the absence of T790M [32]. However, acquired drug resistance against osimertinib is driven by an EGFR-independent. Mature duplex miR-21 yields two miRNAs after separating its two complementary strands into a guide strand [5p] and a passenger strand [3p]. One conventional concept of miRNA biogenesis is that the guide strand is functional, but the passenger strand loses its function due to degradation during the processing step [49]. Since a study has shown a role for the miR-21 passenger strand in carcinogenesis [50], we were curious if the passenger strand of miR-21 was stable during the pathogenesis of drug response and resistance. Surprisingly, miR-21-3p is in the top expressed miRNAs that account for 1% of the total reads in PC9 cells. With treatment of a 3rd generation EGFR inhibitor WZ4002 that shares many common structural features with osimertinib [51] for 24 h, our analysis showed that the normalized reads for miR-21-5p increased 32.6% while miR-21-3p reads remained stable in parental PC9 cells after treatment (Supplementary Fig. 1B). However, in DTPCs derived from PC9, miR-21-3p reads increased by 14.4%, but miR-21-5p reads did not increase (Supplementary Fig. 1B). When the DTPCs were rechallenged with WZ4002 for 48 h, the sequence reads for miR-21-5p increased and miR-21-3p reads decreased slightly (Supplementary Fig. 1B). This data indicates that the expression of miR-21-3p and miR-21-5p are dynamic during drug treatment. Then we asked if the roles of miR-21 in response to EGFR TKIs were similar between growth in two-dimensional (2D) monolayer and 3D cultures. To address this question, we established DTPCs from parental PC9 and HCC827 cells by treating them with 20 nM osimertinib continuously for 2 weeks in 3D cultures (Fig. 1A). Then we performed a small RNA-seq analysis to compare miR-21-5p and miR-21-3p expression between DTPCs and parental cells. We found that miR-21-5p and miR-21-3p expression levels increased 1.5 and 1.8-fold, respectively (Fig. 1B). Consistently, miR-21-3p was abundant compared to most other miRNAs, although the reads for miR-21-5p were lower than those of miR-21-5p in PC9 and HCC827 cells (Fig. 1C and Supplementary Table 1). Thus, these data confirmed that miR-21-5p and miR-21-3p expression increased in DTPCs in both 2D and 3D cultures.

To further explore if miR-21 is functional in transition from a drug-sensitive state to a DTP state, we performed a small-scale expression screening of miR-21-5p and miR-21-3p in a panel of human lung cell lines. They include five EGFR-mutant lung adenocarcinoma cell lines and one immortalized lung epithelial cell line A549 (Supplementary Table 2). Our data demonstrated that H1975 was the cell line with the highest expression level of miR-21-5p and miR-21-3p (Fig. 1D). We then established
osimertinib-tolerant (OTR) cells by continuously treating parental H1975 cells with 100 nM osimertinib for 2 weeks. Our qPCR analysis showed that the expression for both miR-21-5p and miR-21-3p increased in OTR cells compared with parental cells from H1975 (Fig. 1E).

Next, we knocked down miR-21 in H1975 cells with a lentiviral vector targeting miR-21-5p to evaluate the roles of miR-21-5p and miR-21-3p in cells treated with osimertinib (Supplementary Fig. 2A). The real-time PCR analysis demonstrated that miR-21-5p expression was downregulated 40% in cells when miR-21-5p was
knocked down compared with control cells. Surprisingly, expression for miR-21-3p also decreased by 40% in miR-21-5p knockdown cells compared with control cells (Fig. 1F), possibly due to an effect on pre-miRNA processing. To further understand the interactive regulation between the guide and passenger strand, we used a locked nucleic acid (LNA)-modified oligonucleotide synthetic inhibitor against miR-21-5p or miR-21-3p to transfect H1975 cells for 48 h. Our qPCR data showed that expression levels for miR-21-5p and miR-21-3p decreased by 97% and 58% in cells treated with the miR-21-5p inhibitor, respectively (Fig. 1G). Only miR-21-3p expression levels were reduced by 98%, but miR-21-5p levels were not changed significantly in cells treated with the miR-21-3p inhibitor (Fig. 1H). To exclude an off-targeting mechanism from occurring, a perfect complementarity between nucleotide 8 (seed region) of the antisense strand and the passenger strand 3p increased drug tolerance (Fig. 1L) and single-cell-derived colony formation within 14 days by clonogenicity assay in HCC827 cells treated continuously with 40 nM osimertinib (Fig. 1M).

Fig. 1 miR-21 regulates drug tolerance to EGFR tyrosine kinase inhibitors. A Representative images of establishing drug-tolerant persister cells (DTPCs) from HCC827 in 3D cultures in the presence of osimertinib. The 3D cultures were continuously treated with 20 nM osimertinib or vehicle, and images were taken on days 0, 4, and 11. Scale bar, 100 µm. B Relative expression of miR-21-3p and miR-21-5p in DTPCs compared with that in parental cells from PC9 and HCC827. N = 2 replicates. C Normalized reads for top expressed miRNAs by small RNA-seq analysis across gefitinib-tolerant and osimertinib-tolerant cells from PC9 and HCC827. →, highlighting miR-21-5p and miR-21-3p. D qRT-PCR analysis for miR-21-5p and miR-21-3p expression across an immortalized lung epithelial cell (AALE) and EGFR-mutant lung cancer cell lines from humans. miR-423-5p was used as an endogenous control. N = 2−3 replicates. E qPCR analysis for miR-21-5p and miR-21-3p expression in parental and osimertinib-tolerant (OTR) cells from H1975. miR-423-5p was used as an endogenous control. N = 3 replicates. F qPCR analysis for miR-21-5p and miR-21-3p expression in H1975 parental cells treated with a lentiviral miR-21-5p inhibitor. The cells were infected with lentiviral miR-Off-hsa-miR-21-5p virus (lenti anti-miR-21-5p) or a control virus (lenti anti-miR-control) and selected with 0.5 µg/ml puromycin for 3 days. Then RNAs were extracted for qPCR analysis. miR-21-5p and miR-21-3p expression in H1975 cells treated with the LNA miR-21-5p inhibitor and a miRNA control inhibitor 48 h post-transfection. miR-186-5p was used as an endogenous control. N = 3 replicates. G Osimertinib treatment response on H1975 cells infected with the GFP-labeled lentiviral miR-21 inhibitor (anti-miR-21-5p) or scrambled control (anti-miR-control). The cell viability was measured by the CellTiter-Glo luminescent cell viability assay on day 4 after treatment with serially diluted osimertinib. N = 3 replicates. J Osimertinib treatment response on H1975 cells in 3D cultures with the GFP-conjugated lentiviral miR-21 inhibitor (anti-miR-control). The 3D structures were treated with 40 nM osimertinib for 14 days. Images were taken under an EVOS fluorescence microscope. The number of 3D cultures was quantified and analyzed. Scale bar, 1000 µm. N = 3 replicates. K qPCR analysis for miR-21-5p and miR-21-3p expression in HCC827 cells. The cells were infected with the lentiviral miR-a-GFP-hsa-miR-21-5p virus (miR-21-5p OE) or scrambled control and selected with 0.5 µg/ml puromycin for 3 days. Then RNAs were extracted for qPCR analysis. miR-423-5p was used as an endogenous control. N = 3 replicates. L Osimertinib treatment response on HCC827 cells infected with the lentiviral miR-21-5p (miR-21-5p OE) plasmid or scrambled control. The cell viability was measured with the CellTiter-Glo luminescent cell viability assay on day 4 after treatment with serially diluted osimertinib. N = 3 replicates. M Colony formation assay for HCC827 cells infected with the lentiviral miR-21 plasmid (miR-21-5p OE) and scrambled control in 40 nM osimertinib. The number of colonies formed within 14 days was quantified and analyzed. N = 3 replicates. N qPCR analysis for miR-21-5p and miR-21-3p expression in HCC827 cells treated with 40 nM LNA miR-21-3p mimic, miR-21-5p mimic and a negative miRNA mimic control (NC). miR-423-5p was used as an endogenous control. N = 3 replicates. O Osimertinib treatment response on HCC827 cells transfected with the LNA miR-21-3p mimic, miR-21-5p mimic, and a negative miRNA mimic control in the presence or absence of osimertinib. Twenty-four hours post-transfection with the 40 nM miRNA mimic, the cells were treated with 1 µM osimertinib for 6 days, followed by CellTiter-Glo luminescent cell viability assay. N = 4 replicates. Data are mean ± s.e.m. and were analyzed with an unpaired two-tailed t-test (D, F, G, H); unpaired two-tailed t-test with Welch’s correction (E, K, M); Kruskal–Wallis ANOVA (J); Brown–Forsythe and Welch ANOVA (N, O).
MiR-21 regulates purine metabolism leading to a DTP state

Previous studies showed that miR-21-5p induced drug resistance to the 1st generation of EGFR-TKI gefitinib through decreasing expression of tumor suppressor phosphatase and tensin homolog (PTEN) or programmed cell death protein 4 (PDCD4) in gefitinib/erlotinib-resistant PC9 (PC9ER) cells [47, 55]. We found that knocking down miR-21-5p with 120 nM of LNA inhibitor did not increase the expression of PTEN and PDCD4 (P = 0.92 and P = 0.73, respectively) in PC9ER cells. Knocking down miR-21-3p with 120 nM of LNA inhibitor increased the expression of PTEN (P = 0.012) (Supplementary Fig. 5A). In H1975 cells, LNA miR-21-3p inhibitor treatment reduced PTEN expression (P = 0.008) but increased PDCD4 expression (P = 0.018). Treatment with the miR-21-5p inhibitor did not significantly change PTEN or PDCD4 expression in H1975 cells (Supplementary Fig. 5B). Thus, our data have demonstrated that blocking miR-21-3p rather than miR-21-5p increased PTEN and PDCD4 expression in PC9ER and H1975 cells, respectively. This indicates that the mechanisms of miR-21-5p and miR-21-3p in regulating PTEN and PDCD4 are cell context-dependent.

Metabolic changes tune drug response in current anticancer therapies [56]. We hypothesized that treatment-induced metabolite dysregulation could regulate the transition from the drug-sensitive state to the DTP state. First, we asked if metabolite changes could distinguish DTPCs from parental cells. We performed a metabolomics analysis of parental and DTPCs from H1975 with a liquid chromatograph-mass spectrometry (LC-MS) tool to address this question. The top dysregulated metabolic pathways in comparing DTPCs and parental cells were purine metabolism, alanine, aspartate and glutamate metabolism, aminoacyl-tRNA biosynthesis, pyrimidine metabolism, nitrogen metabolism, arginine, and proline metabolism as well as citrate metabolism, arginine, and proline metabolism, aspartate, and glutamate, pathways in comparing DTPCs and parental cells were purine metabolism, Alanine, aspartate, and glutamate, metabolism, arginine, and proline metabolism.

We performed a metabolomics analysis of parental and DTPCs from H1975 with a liquid chromatograph-mass spectrometry (LC-MS) tool to address this question. The top dysregulated metabolic pathways in comparing DTPCs and parental cells were purine metabolism, Alanine, aspartate, and glutamate metabolism, arginine, and proline metabolism as well as citrate metabolism, arginine, and proline metabolism.

Our analysis showed that the top upregulated metabolites in DTPCs versus parental cells were cholesterol, adenylosuccinate (also called succinyladenosine monophosphate or S-AMP), cytidine, acetyl coenzyme A (acetyl-CoA), and N-acetyl-glutamate (Fig. 2B and Supplementary Table 3). The top downregulated metabolites were CoA, glutathione, aminomidozale carboxamide riboside (AICAR or acadesine), and S-adenosylhomocysteine (SAH) (Fig. 2B and Supplementary Table 4).

Among the list of top upregulated metabolites, S-AMP is an intermediate in the interconversion of purine nucleotides inosine monophosphate (IMP) and adenosine monophosphate (AMP) catalyzed by ADSL [4]. Cytidine is a pyrimidine nucleoside molecule that is found in RNA. Acetyl-CoA delivers the acetyl group to the tricarboxylic acid cycle to be oxidized for ATP generation. N-acetyl-glutamate is biosynthesized from acetyl-CoA or acetylornithine and is involved in the urea cycle (Supplementary Table 3).

Among another list of top downregulated metabolites, CoA is involved in fatty acid biosynthesis and ATP production. Glutathione is an antioxidant and can overcome reactive oxygen species (ROS)-induced cellular damage [59]. AICAR is an intermediate metabolite in purine de novo biosynthesis and mimics AMP to stimulate AMP-activated protein kinase (AMPK) [60, 61]. SAH is derived from 5'-adenosylmethionine (SAM) and is converted into homocysteine and adenosine. Besides AMP, S-AMP, and AICAR in the purine metabolism synthesis pathway [62], other metabolites in the purine degradation pathway also show significant changes, including upregulated inosine, urea, urate, xanthosine, xanthine, inosine diphosphate (IDP), adenine, and guanosine diphosphate (GDP) (Fig. 2B, C and Supplementary Table 4). The high levels of purine degradation products might be related to the increased recycling of these degraded purines into building blocks for the DNA and RNA synthesis [63].

Then we asked if the metabolic changes in DTPCs were rescued by miR-21 perturbation. Because the lentiviral miR-21-5p inhibitor could decrease expression of both miR-21-5p and miR-21-3p to a similar extent, we introduced this vector in OTR cells from H1975 and performed metabolomic analysis. Interestingly, acadesine, the non-phosphorylated form of AICAR was the most upregulated metabolite after miR-21 knockdown (Fig. 2D). Similarly, reduced AICAR level in OTR cells was also upregulated twofold upon miR-21 knockdown (Supplementary Table 5). All the other metabolites in purine metabolism consistently demonstrated partially reversed changes after miR-21 knockdown in DTPCs (Fig. 2C). Our data confirmed a link between miR-21 and purine metabolism in lung cancer cells.

We asked if AICAR treatment could prevent miR-21-induced transition to the DTP state to test if this was a functional link. We added AICAR in parental H1975 cells with or without osimertinib and performed a drug response assay. Our results showed that AICAR monotherapy of less than 0.12 mM did not decrease cell viability obviously (Fig. 2E). Using the Bliss independence model [64], AICAR and osimertinib showed synergistic effects, with a 29 ± 4% increase in drug sensitivity in H1975 cells treated with 0.01 μM osimertinib and 0.11 mM AICAR compared to predicted levels (Fig. 2F). This suggests that AICAR can further increase osimertinib-induced drug response. Our data have revealed that the miR-21-induced DTP state is via a reduction of AICAR in purine metabolism.

ADSL is targeted by MiR-21 directly leading to dysregulation of purine metabolism

AICAR is the primary product of ADSL metabolism in de novo purine biogenesis. Thus, we inferred that ADSL repression leads to a reduced level of AICAR in the DTPCs. Our experimental evidence showing a negative correlation between AICAR levels and expression of miR-21-5p and miR-21-3p indicates that miR-21 might reduce AICAR levels via suppressing ADSL expression. We utilize complementary approaches including computational prediction and experimental validation to test the direct interaction between miR-21 and ADSL to validate this hypothesis. We tested if miR-21-5p or miR-21-3p could regulate ADSL directly. Computational prediction of miRNA downstream target using the TargetScan tool showed that ADSL mRNA has a sequence that could be bound directly by miR-21-3p (Fig. 3A).

Next, we performed dual transfection in H1975 cells using an oligonucleotide containing LNA miR-21-3p inhibitor and a wild-type (WT) ADSL 3′ UTR plasmid. The dual-glo firefly/renilla luciferase data demonstrated that blocking miR-21-3p increased WT ADSL 3′UTR activity 1.4-fold (P = 0.006) compared to the control group (Fig. 3B). To address if miR-21-5p binds to ADSL directly, we used a similar strategy of the dual-lucerase assay for 3′UTR activity of ADSL by blocking miR-21-5p in H1975 cells. Our data showed that inhibiting miR-21-5p with the synthetic LNA inhibitor against miR-21-5p increased ADSL 3′UTR activity by 1.7-fold (P = 0.008) (Fig. 3C). To further understand the binding specificity to the ADSL 3′UTR by miR-21, we constructed a mutant ADSL 3′UTR plasmid by changing a sequence of GGTTGT to GCACAT (Fig. 3A). As expected, inhibiting miR-21-3p did not significantly reduce the dual-glo lucerase activity of mutant ADSL 3′UTR (P = 0.08). Similarly, blocking miR-21-5p did not substantially decrease the dual-glo lucerase activity of mutant ADSL 3′UTR (P = 0.487). These data demonstrated that miR-21-5p directly regulates ADSL.

Furthermore, we anticipated that ADSL protein levels would be downregulated in the DTPCs due to increased levels of miR-21-3p. Western blot analysis showed that ADSL protein levels decreased in OTR cells compared to parental cells from H1975 (P = 0.044) (Fig. 3D and Supplementary Fig. 6A, B). Then we reduced the abundance of miR-21-5p and miR-21-3p using the LNA inhibitor against miR-21-5p in H1975 OTR cells. We found that blocking
miR-21-5p effectively increased ADSL protein levels in OTR cells ($P = 0.027$) (Fig. 3E and Supplementary Fig. 6C, D). Blocking the passenger strand with the synthetic LNA inhibitor against miR-21-3p also increased ADSL protein expression in H1975 parental cells ($P = 0.027$) (Fig. 3F and Supplementary Fig. 6E, F). These data confirmed that miR-21-3p and miR-21-5p repress ADSL protein expression.

Using a bioinformatic tool, Lung Cancer Explorer [65], we performed a correlation analysis between expression for precursor MIR21 and ADSL mRNA across 292 lung cancer patient tissues. The
analysis showed that \( \text{miR-21 is negatively correlated to ADSL gene expression in three independent datasets} \) \((r = -0.38, P = 0.000043, n = 111 \) tumors, GSE3141 [66]; \( r = -0.49, P = 0.000974, N = 43 \) tumors, GSE16534 [67]; \( r = -0.25, P = 0.002655, n = 138 \) tumors, GSE8894 [68]). (Fig. 3G and Supplementary Tables 6–9). These data suggest that miR-21 is negatively correlated to ADSL.

These data validated our hypothesis on miR-21 as a direct repressor of ADSL. Several studies have proved that one miRNA may target multiple genes belonging to the same signaling pathway in lung cancer [69, 70]. Therefore, we asked if miR-21 could target other enzymes in the purine biosynthesis pathway besides ADSL. The purine de novo biogenesis pathway provides adenine and guanine building blocks for RNA and DNA synthesis [71]. The six metabolic enzymes including phosphoribosyl pyrophosphate amidotransferase (PPAT), phosphoribosylaminomidazole synthetase (GART), phosphoribosylformylglycinamide synthase (PFAS), phosphoribosylaminomidazole carboxylase (PAICS), ADSL and aminoimidazole carboxamidofomyltransferase (AICAR transforamlyase, ATIC) form the purinosome temporarily to catalyze phosphoribosyl pyrophosphate (PRPP) to IMP [72]. Complementary to the de novo purine synthesis pathway, the purine nucleotide cycle generates ammonia and fumarate from aspartate and IMP. These reactions are catalyzed by three enzymes, including adenosine monophosphate deaminase 2 (AMPD2), adenylosuccinate synthase (ADSS), and ADSL (Fig. 3H).

Using the TargetScan tool, we found that other enzymes in the purine pathway are predicted targets of miR-21-5p and miR-21-3p. The anticipated miR-21-5p target genes include PPAT and ATIC. The predicted miR-21-3p target genes include PPAT, PAICS, ADSL, ADSS, and AMPD2. GART and PFAS were not listed as the predicted target genes of miR-21-5p and miR-21-3p. To investigate if any of these are confirmed targets of miR-21-5p and miR-21-3p, we looked at the Tarbase, a database of experimentally verified miRNA–gene interactions [73]. Only one report described an enhanced association of miR-21-3p with GART in human kidney 293S cells upon cellular stress [74]. Furthermore, our western blot analysis showed that these enzymes did not significantly decrease their expression in the OTR cells including PPAT \((P = 0.20)\), GART \((P = 0.45)\), PFAS \((P = 0.078)\), PAICS \((P = 0.33)\), ATIC \((P = 0.42)\), AMPD2 \((P = 0.73)\), and ADSS \((P = 0.44)\) (Fig. 3I and Supplementary Fig. 7A–G). Blocking miR-21-5p with the LNA inhibitor against miR-21-3p did not significantly upregulate expression of these targets in H1975 OTR cells compared with cells treated with the control miRNA inhibitor (Fig. 3J and Supplementary Fig. 8A–G). These data suggest that miR-21-5p and miR-21-3p inhibit ADSL in purine metabolism in the DTPCs.

Due to one-carbon metabolism providing carbons for purine biogenesis [75], we asked if one-carbon metabolism was linked to the DTPCs driven by miR-21. ATIC uses 10-formyltetrahydrofolate (FTFH) for purine synthesis [76]. FTHF is converted from 5,10-methylenetetrahydrofolate (MTHF) by methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2 (MTHFD2) in mitochondria and from formate by MTHFD1 in the cytosol [77]. By analyzing TargetScan, we found that MTHFD1 is a predicted target gene of miR-21-3p and miR-21-5p and MTHFD2 is a predicted target of miR-21-3p. The consumption of AICAR needs MTHF as a cofactor catalyzed by ATIC. We hypothesized that the increased MTHF contributed to reduced AICAR levels. To test this hypothesis, we measured MTHFD1 and MTHFD2 expression. Western blot data showed that expression of MTHFD1 and MTHFD2 did not significantly decrease in the OTR cells compared with parental cells (Fig. 3K and Supplementary Fig. 9A, B). Blocking miR-21-5p with the miR-21-5p inhibitor did not significantly increase the expression of MTHFD1 and MTHFD2 (Fig. 3L and Supplementary Fig. 9C, D). This indicates that one-carbon metabolism might not be involved in miR-21-mediated purine metabolism. Blocking the passenger strand with the synthetic LNA inhibitor in the parental H1975 cells did not change GART \((P = 0.99)\) and PAICS \((P = 0.54)\) protein expression. Still, it increased PPAT expression significantly \((P = 0.014)\) (Fig. 3M and Supplementary Fig. 10A–C). This suggests that miR-21-3p can regulate PPAT besides ADSL in purine metabolism. Inhibiting the guide strand with the LNA miR-21-5p inhibitor did not significantly change expression of PPAT \((P = 0.67)\), GART \((P = 0.45)\), and PAICS \((P = 0.81)\). Thus, our data suggest that miR-21-5p and miR-21-3p regulate purine metabolism mainly through turning ADSL.

Blocking miR-21 increases reactive oxygen species and co-treatment with AICAR and osimertinib reduces antioxidant response

We asked how a miR-21-ADSL-AICAR-purine signaling axis regulates drug tolerance to EGFR inhibitors. As an analog of AMP, AICAR activates AMP-activated protein kinase (AMPK) [78] leading to imbalanced ROS or redox status [79]. We asked if AMPK was inactivated in DTPCs compared with parental cells. As expected, western blot data demonstrated that phosphorylated AMPK (p-AMPK) was significantly downregulated in the OTR cells compared to parental cells from H1975 \((P = 0.0036)\) (Fig. 4A and Supplementary Fig. 11A–C). And the reduced p-AMPK expression in the OTR cells was partially rescued by miR-21-5p knockdown \((P = 0.039)\) (Fig. 4A and Supplementary Fig. 11A–C). In parental H1975 cells, expression of p-AMPK \((P = 0.34)\) and phosphorylated acetyl-CoA carboxylase (p-ACC) \((P = 0.64)\) and \(P = 0.99)\), respectively) was not changed significantly when treated with the LNA inhibitors against miR-21-3p and miR-21-5p (Fig. 4B and Supplementary Fig. 12A–D). These data indicated that miR-21 inhibition activates AMPK signaling pathway in the OTR cells.

AMPK senses and restores energy homeostasis and the redox balance [80]. We asked if miR-21 regulates ROS levels in our conditions. Our result showed that knocking down miR-21-5p dramatically increased ROS levels in the OTR cells more than the control and miR-21-3p inhibitors \((P = 1.1e-05)\) (Fig. 4C), supporting previous evidence demonstrating targeting redox imbalance to overcome drug resistance [81]. This indicates that miR-21-5p plays...
an important role in keeping redox balance. To determine if AICAR mediates ROS generation, we measured cellular ROS levels in H1975 parental cells treated with 1 mM AICAR at different time points by flow cytometry analysis using a deep red ROS assay. ROS levels increased as early as 2 h after 1 mM AICAR treatment, and the increased ROS levels remained stable for 24 h (Fig. 4D and Supplementary Fig. 13A). Interestingly, 1 µM osimertinib treatment increased ROS generation gradually between 2 and 8 h post-induction. ROS levels fell at 24 h post-treatment with osimertinib (Fig. 4D and Supplementary Fig. 13B). The data support the idea
that dysregulated AICAR-ROS signaling is relevant to the DTP state transition. We hypothesized that AICAR in combination with osimertinib could further increase ROS generation. We performed flow cytometry analysis to measure ROS levels 4 h after treatment with AICAR, osimertinib, and combo to address this question. Our data showed that a combination of AICAR and osimertinib could upregulate miR-21-5p or miR-21-3p expression through activating NRF2. We performed a qRT-PCR analysis of miR-21-3p and miR-21-5p in cells treated with hydrogen peroxide (H2O2) for 4 h to test the hypothesis. Our data showed that increasing doses of H2O2 induced miR-21-3p and miR-21-5p upregulation in the cells treated with hydrogen peroxide (H2O2) for 4 h, which was consistent with our previous findings (Supplementary Fig. 15C, D). This indicates that AICAR might block miR-21-3p and miR-21-5p upregulation by targeting NRF2.

It was reported that reduced purine metabolism led to cancer cell differentiation [84] and differentiated cancer cells are more vulnerable to stress such as oxidant stress [85]. We hypothesized that AICAR treatment decreases antioxidant response in tumor cells treated with EGFR TKIs. Our western blot data on NRF2 expression demonstrated an increase in H1975 cells after osimertinib treatment (P < 0.017), indicating an increased antioxidant response in tumor cells induced by osimertinib treatment (Fig. 4H and Supplementary Fig. 16A, B). This increase in NRF2 expression was reduced dramatically (P = 0.031) when AICAR was co-administered with osimertinib (Fig. 4H and Supplementary Fig. 16A, B). These data indicated that AICAR co-treatment with osimertinib could prevent antioxidant response in tumor cells.

Knocking out MIR21 induces the concurrent increase of purine metabolism and decreased glutathione metabolism

Since miR-21 regulates purine metabolism in our cultured lung cells in vitro, we tested which metabolic pathways could be modulated by miR-21 in physiological conditions. Utilizing a unique MIR21 knockout (KO) mouse model [86], we did not find any noticeable phenotypic changes in the MIR21 KO mice compared with wild-type littermates when grown under standard laboratory conditions for the length of the study. We collected whole lung tissues from 8-week-old animals (males and females) and performed metabolomics profiling (Fig. 5A). Metabolic pathway analysis showed that the top significantly changed pathways were purine metabolism, cysteine and methionine metabolism, pyrimidine metabolism, citrate cycle (TCA cycle), and pyruvate metabolism (Fig. 5B). Consistent with our in vitro data, this in vivo data further demonstrated that dysfunction of purine metabolism was the top metabolic change in lung tissues when the MIR21 gene was lost. Among differentially expressed metabolites (Supplementary Table 10), the top downregulated metabolites were cysteine, pyridoxine, methionine, and succinate (Fig. 5C). And top upregulated metabolites were ATP, dGTP, propionyl-CoA, and UDP-D-glucurionate (Fig. 5C). In the top dysregulated pathway of purine metabolism, many metabolites were upregulated after MIR21 was knocked out (Fig. 5D). The AICAR level was upregulated 1.5-fold in MIR21 KO lung tissues compared with WT lung tissues (Fig. 5E). Other upregulated purine metabolites included IDP, IMP, inosine, hypoxanthine, xanthine, guanine, guanosine, GDP, GTP,
Fig. 4 AICAR induces reactive oxygen species generation and prevents transition to drug tolerance. A Western blot analysis of p-AMPK and AMPK in parental and osimertinib-tolerant (OTR) cells from H1975 and OTR cells with the miR-21-5p inhibitor (anti-21-5p) and scrambled control (anti-miR-control), p-AMPK was used as the loading control. The p-AMPK (Thr172) quantification was normalized to the total AMPK in comparing OTR versus parental cells and OTR anti-miR-control versus OTR anti-miR-21-5p cells. N = 3 replicates. B Western blot analysis and quantification for p-AMPK, AMPK, p-ACC, and ACC in H1975 cells treated with the LNA inhibitor against miR-21-3p (anti-miR-21-3p), miR-21-5p (anti-miR-21-5p), and a miRNA control (anti-miR-control). Total AMPK and total ACC were used as loading controls to quantify p-AMPK and p-ACC. N = 2 replicates. C Flow cytometry analysis for ROS levels in OTR cells with the LNA inhibitor against miR-21-3p (anti-miR-21-3p), miR-21-5p inhibitor (anti-miR-21-5p), and a scrambled control (anti-miR-control) from H1975. The OTR cells were transfected with 120 nM LNA inhibitors labeled with fluorescein amidite (FAM), followed by flow cytometry analysis for ROS levels 8 h post-transfection. N = 4 replicates. D Timepoint ROS assay for H1975 parental cells treated with AICAR and osimertinib. The cells were treated with 1 mM AICAR (left) or 1 µM osimertinib (right) for 0, 2, 4, 6, 8, and 24 h followed by incubation with cellular ROS deep red dye. Then the deep red positive cells were analyzed by flow cytometry analysis. N = 4 replicates. E Representative images of flow cytometry analysis for ROS levels from H1975 parental and osimertinib-tolerant (OTR) cells treated with 120 nM LNA inhibitors labeled with fluorescein amidite (FAM), followed by flow cytometry analysis for ROS levels 8 h post-transfection. N = 4 replicates. F Statistical analysis of ROS levels in H1975 parental and osimertinib-tolerant (OTR) cells treated with AICAR, osimertinib, AICAR combined with osimertinib, and negative control. N = 3-4 replicates. G Western blot analysis and quantification for NRF2 in H1975 parental cells treated with 1 mM AICAR for 0, 1, 2, 4, 6, 8, and 24 h. β-Actin was used as the loading control. N = 2 replicates. H Western blot analysis for NRF2 in H1975 parental cells treated with AICAR (1 mM), osimertinib (1 µM), AICAR (1 mM) combined with osimertinib (1 µM) and negative control for 4 h. β-Actin was used as the loading control. N = 3 replicates. Data are mean ± s.e.m and were analyzed with unpaired two-tailed t-test (A); RM ANOVA (B); Brown–Forsythe and Welch ANOVA (C); Kruskal–Wallis ANOVA (F, H); one-way ANOVA (G).
Fig. 5 Knocking out MIR21 promotes purine metabolism and decreases glutathione metabolism. A Principal component scores (PCA) of metabolites in whole lung tissues from wild-type (WT) and MIR21 knockout (KO) mice. \( N = 6 \) replicates. B Metabolic pathway analysis of lung tissues from MIR21 KO and WT mice. \( N = 6 \) replicates. C Top 40 metabolic hits differentially expressed in the lung tissues from MIR21 WT and KO mice. \( N = 6 \) replicates. D A diagram of purine metabolism. Red font indicates upregulated metabolites in comparing MIR21 KO and WT mouse lung tissues. E Upregulated metabolic hits in purine metabolism in lung tissues from the MIR21 KO mice compared with WT mice. \( N = 6 \) replicates. F Downregulated and upregulated metabolic hits in the glutathione metabolism pathway in lung tissues from MIR21 KO mice compared with WT mice. \( N = 6 \) replicates. G The ratio of glutathione disulfide (GSSG)/glutathione (GSH) in lung tissues from MIR21 KO mice compared with WT mice. \( N = 6 \) replicates. Data are mean ± s.e.m. and were analyzed with an unpaired two-tailed t-test (A, B, C, G).
dGTP, adenine, dAMP, ADP, and ATP. The levels of ribose-phosphate and glutamine that provide ribose and nitrogen for the synthesis of purine were also upregulated 1.5-fold and 1.4-fold, respectively (Fig. 5E).

Our previous data showed that AICAR-induced ROS increased in vitro. ROS is eliminated by endogenous and exogenous antioxidant metabolites such as glutathione and ascorbic acid [87]. We tested if knocking out MIR21 could regulate glutathione metabolism. Our data demonstrated that metabolites including ascorbic acid, cysteine, and pyroglutamic acid were down-regulated in MIR21 KO lung tissues (Fig. 5F). Further analysis showed that the ratio of glutathione disulfide (GSSG)/glutathione (GSH) increased 2.4-fold when MIR21 was deleted in the lung tissues ($P = 2.5E-05$) (Fig. 5G). These indicate that MIR21 KO decreased ROS scavenging capacity in the mouse tissues. Collectively, our in vivo data confirmed MIR21’s role in regulating purine metabolism and glutathione metabolism.

**DISCUSSION**

The purine de novo biogenesis and degradation pathway provides adenine and guanine building blocks for RNA and DNA synthesis [71]. The six metabolic enzymes, including PPAT, GART, PFAS, PAICS, ADSL, and ATIC, form a purinosome temporarily to catalyze PRPP to IMP [72]. In the presence of EGFR-TKI osimertinib, some drug-sensitive parental cells transit to the DTP state resulting in the survival of cells in the stress [88]. Our metabolomics analysis of the DTPCs showed that purine metabolism is the top signaling pathway demonstrating an increase of a panel of metabolites in purine metabolism except for AICAR. Supported by previous discoveries showing that increasing amounts of purine metabolites promote cancer cells’ proliferation [57, 89], our data suggest that increasing purine degradation products might promote survival of the DTPCs under osimertinib-induced stress. Concurrent to the increased purine degradation blocks in the DTPCs, other metabolites providing nitrogen atoms of the purine ring such as glutamine levels also increased in our metabolomics data (Supplementary Table 3). These data support a comprehensive increase of purines in the DTPCs. Strikingly, as an intermediate metabolite in purine de novo biosynthesis, AICAR is one of the most downregulated metabolites in the DTPCs compared with parental cells. AICAR is converted from SAICAR by ADSL and is catalyzed into FAICAR by ATIC. A reduction of AICAR indicates ADSL is silenced or ATIC is upregulated. Our western blot assay demonstrated more decreases in ADSL than ATIC in the OTR cells, indicating that these changes might cause less supply of AICAR, resulting in reduced AICAR levels in the DTPCs. Another proof supporting silenced ADSL is an increase of S-AMP in the DTPCs because S-AMP is converted to AMP by ADSL in the purine nucleotide cycle. Thus, our data first demonstrate silenced ADSL and reduced AICAR in the DTPCs in lung cancer. Clinically most ADSL-deficient children display marked psychomotor delay and accumulation of SAICAR but reduced AICAR [90]. Our innovative discovery of inactivated ADSL-AICAR signaling in the DTPCs may direct a clinical study in lung cancer patients who receive EGFR TKIs and then undergo the DTP state transition in the future. Our study first links reduced AICAR and ROS to the acquisition of the DTP state in lung cancer cells. Supporting our findings, it has been recently reported that a signature in DTPCs has lower ROS levels and higher NRF2 expression after drug treatment than in untreated cells in the lung and other cancers [91]. Our study rescued this reduced level of ROS by treating parental cells with AICAR resulting in re-sensitizing DTPCs to osimertinib in H1975 cells. Increasing AICAR leading to reduced antioxidant NRF2 expression indicates that the lung tumor cells might control ROS at low levels to avoid oxidative damage. This mechanism was supported by evidence of reduced glutathione levels in these DTPCs from our data. Further proof of decreased expression of NRF2 protein after combination treatment of AICAR and osimertinib provides a possible mechanism for the parental cells being more vulnerable to AICAR-induced ROS. Thus, our data confirm the effects of AICAR in preventing the acquisition of the DTP state by regulating ROS levels in lung cancer cells. A previous study demonstrated reduced ROS levels in some breast cancer stem cells compared with noncancer stem cells [85]. Cancer stem cells have been described to contribute to drug resistance in many cancers via an intrinsic mechanism [92, 93]. Although the DTP state is acquired in the DTPCs, our previous study has shown partially overlapping genes between DTPCs and cancer stem cells [14]. The DTPCs may acquire some CSC features leading to less responsiveness to treatment by a de-differentiation mechanism. Stimulation of purine biosynthesis promotes stemness in some cancers [84]. Here AICAR inhibits purine metabolism by blocking the enzyme ADSL. Thus, it is reasonable to speculate that AICAR might promote cancer differentiation, allowing the differentiated cancer cells are more sensitive to osimertinib. It will be interesting to understand how DTPCs acquire features of cancer stem cells through AICAR-mediated purine metabolism in the future.

Consistent with the data in previous studies in drug-resistant lung cancer [47, 94], we also found an increase of miR-21-5p expression in the DTPCs compared to parental cells. The left guide miRNA strand (5p, left arm) is bound to another right passenger strand [3p] composing a miRNA duplex in the cytoplasm. Few studies look at the passenger strand of miR-21 due to a conventional concept regards this passenger strand being degraded after separating from the guide strand [95]. Our data challenged the notion that miR-21-3p expression is abundant in acquiring the DTP state in cancer cells. This suggests that degradation of miR-21-3p might be delayed or interrupted in the DTPCs compared to parental sensitive cells. The concurrent dysregulation of miR-21-5p and miR-21-3p in the acquisition of the DTP state and post-transfection of miR-21-5p with the LNA inhibitor suggest that miR-21-5p might increase miR-21-3p stability in the context of drug tolerance. Supporting this hypothesis, the treatment with hydrogen peroxide upregulated the expression of both strands in both parental and DTPCs from H1975. Consistent with our discovery, other studies found that guide and passenger arms become stable by binding to argonaute 1 and argonaute 2, respectively [96, 97]. Another possible mechanism might be relevant to miRNA arm switching due to a modification of the passenger strand that causes alternative processing by Dicer 1, ribonuclease III (DICER1), and selection of the passenger strand [98]. It will be interesting to explore mechanisms of strand selection impacted by post-transcriptional modifications on miRNAs and their binding to argonaute.

Our study has demonstrated that both strands of miR-21 are abundant in expression and activity in regulating ADSL in the purine metabolism pathway. We found that miR-21-3p directly represses ADSL expression. Strikingly, miR-21-5p also regulates ADSL expression in a similar way to miR-21-3p. This role of miR-21-5p might be an indirect regulation of ADSL via miR-21-3p. In addition to targeting ADSL, miR-21-3p represses apoptotic factors, including PTEN and PDCD4 in PC9ER and H1975 cells. Collectively, our data indicate that the miR-21 family members coordinate with each other to regulate the acquisition of the DTP state by targeting the apoptosis and purine metabolism pathway. It will be interesting to expand the miR-21-mediated network using new approaches such as in silico models [99].

This is the first report that miR-21-3p is enhanced in the DTPCs in lung cancer together with miR-21-5p. miR-21-5p and miR-21-3p increase cells’ drug tolerance by regulating the purine metabolism and oxidative stress pathway. Our data showing synergy between AICAR and osimertinib provides a promising direction for targeting purine metabolism and oxidative stress in preventing drug tolerance against anti-EGFR therapy in the future.
METHODS

Cell culture and cell lines
Each cell line was maintained in a 5% CO₂ atmosphere at 37 °C. Human lung EGFR-mutant cell lines H1650, H1975, HCC827, PC9, and H3255 (provided by Dr. Susumu Kobayashi) were cultured in DMEM (high glucose) ( Gibco) with 10% FBS, 2 mM L-glutamine and 1% penicillin-streptomycin. Immortalized tracheobronchial epithelial AALE cells (provided by William C. Hahn) were derived as previously described [100] and maintained in SAGM media (Lonza). Cell lines were negative for mycoplasma using the MycoAlert Kit (Lonza).

3D cultures
Single-cell suspensions (2000 cells/well/20 μl) were co-plated with geltrex (25 μl) in 96-well non-treated clear plates (Corning, Cat# 08-772-53). The plate was incubated for 20 minutes at 37 °C, and 100 μl of complete growth media were added. The complete growth media was advanced DMEM supplemented with glutaMAX [1X], HEPES [1X], 1.25 mM N-acetylcysteine, 10 mM nicotinamide, 10 μM Forskolin, B27 [1X], 5 ng/ml Noggin, 100 ng/ml FGF10, 20 ng/ml FGF2, 50 ng/ml EGF, 10 ng/ml PDGFA, 10 ng/ml FGF7, and 1% penicillin-streptomycin as mentioned previously [14]. The media was changed every 3 days in 24 days. The phase-contrast 3D cultures were photographed from three random fields per group under a microscope (Evos FL, Life Technology).

MIR21 knockout mouse model
Both wild-type (strain# B6129SF2/J and stock# 101045) and MIR21 knockout mice (strain# B6129S6-Mir21a−/−) Homozygote or MIR21 null and stock# 016856) [86] in males and females were purchased from the Jackson Laboratory. The animal protocol was approved by Beth Israel Deaconess Medical Center Biological Resource Center Institutional Animal Care and Use Committee (IACUC). Both males and females at 8 weeks of age were randomly used for isolating lung tissues for metabolomics study. The whole lung tissues were isolated from mice immediately after euthanasia. After a quick rinse with cold PBS, the lung tissues were chopped into small pieces, followed by fast freezing by liquid nitrogen. Six mice-derived lung tissues from each group proceeded to the metabolomics study. Investigators were blinded to the group allocation during the procedure and metabolomics analysis.

Antibodies and reagents
For western blotting, primary anti-p-AMPK (Thr172, clone 40H9) (1:500, Cat# 2535s), anti-AMPK (1:1000, Cat# 2532s), anti-p-ACC (Ser79, 1:500, Cat# 3661s), anti-ACC (1:1000, Cat# 3662s), anti-PFAS (1:1000, Cat# 61852s) anti-PTEN (1:1000, Cat# 9552s), and anti-PDCD4 (1:1000, Cat# 9535s) antibodies were from Cell Signaling Technology. Primary anti-ATIC (1:1000, clone C-3, Cat# sc-365402), anti-GART (1:1000, clone F-8, Cat# 66447), anti-MTHFD1/1 L (1:1000, clone D-9, Cat# sc-376372), anti-MTHFD2 (1:1000, clone A-9, Cat# sc-390708), anti-AMPD2 (1:1000, clone QQ13, Cat# sc-100504), and anti-NRF2 (1:1000, clone A-10, Cat# sc-365499) antibodies were from Santa Cruz Biotechnology. Primary anti-PPAT (1:1000, Cat# Ab125864) and anti-ADSS/ADSS2 (1:1000, clone EPR12331-52, Cat# Ab174842) antibodies were from Abcam. Primary anti-PAICS (1:1000, clone 2C9, Cat# GTX83950) was from GeneTex. Primary anti-ADSL (1:500, Cat# HPA000525) was from Sigma-Aldrich. Mouse anti-β-actin (1:10,000, clone C4, Santa Cruz, Cat# sc-47778) was used as a loading control. Secondary goat anti-rabbit (1:1000, Cat# 32460) and goat anti-mouse (1:1000, Cat# 32430) antibodies were purchased from Thermo Fisher Scientific.

Small molecules
Osimertinib (Cat# S7297), WZ4002 (Cat# S1173), and gefitinib (Cat# S1025) were purchased from Selleck Chemicals. AICAR (Cat# 2840) was purchased from Tocris. H₂O₂ (Cat# H1009-100ML) was purchased from Sigma-Aldrich.

Small molecule treatment
AICAR, osimertinib, WZ4002, and gefitinib were reconstituted in sterile dimethyl sulfoxide (DMSO) at a stock concentration of 200 mM, 10 mM, 10 mM, and 20 mM, respectively. H₂O₂ was diluted in growth media (DMEM supplemented with 10% FBS and 1% penicillin-streptomycin) to achieve 0, 0.5, and 1 mM concentrations. To achieve the required concentration, the compound of interest was serially diluted in growth media for mono treatment. For combination treatment, AICAR and osimertinib were serially diluted in growth media to achieve 2x of the necessary concentration and were combined to get the 1x working concentration.

To establish osimertinib-tolerant (OT) cells, the parental cells were treated with 20 nM osimertinib or a vehicle for 14 days from HCC827 and PC9. To establish osimertinib-tolerant cells, the parental H1975 were continuously treated with 100 nM osimertinib for 2 weeks. To establish WZ4002-tolerant DTPCs in PC9, the parental PC9 were treated by culturing in 300 nM WZ4002 for 2 weeks.

For cells with a short-term response to WZ4002, the parental PC9 cells were treated with 1 μM WZ4002 or a vehicle for 24 h. The WZ4002-tolerant cells were taken out of the drug for 48 h prior to being rechallenged with WZ4002 or a vehicle for 48 h.

Cell viability assay
Cells (3 x 10⁵/well) were seeded in 96-well plates (Falcon) in three replicates. After 6 h of plating, the spent medium was replaced with a fresh medium containing vehicle or serially diluted solutions of AICAR or osimertinib. At 3 days post-drug treatment, 50 μl of CellTiter-Glo (Promega, Cat# G7570) was added to each well. The samples were incubated for 10 min in the dark before detection with the EnVision plate reader (Perkin-Elmer). For combination treatment, cells (3 x 10⁵/well) were seeded in four 96-well plates, each representing an independent replicate. After 6 h of plating, the spent medium was replaced with a medium containing AICAR and osimertinib at the indicated concentrations.

The cell viability was measured by CellTiter-Glo luminescent assay.

Western blots
H1975-derived parental, OTR, OTR with a scrambled control and mir-21 inhibitors were treated in different groups at concentrations of 0.1 μM of osimertinib and 1 mM of AICAR for 24 h. For measuring protein changes at various time points, H1975 cells were treated with 1 mM AICAR for 0–24 h. Cells were then lysed with 300 μL RIPA buffer (Thermo Fischer Scientific) with a cocktail of inhibitors against protease and phosphatase (Thermo Fischer Scientific). The collected cells were centrifuged for 40 min at 15,000 rpm at 4 °C, followed by a collection of the supernatant. Protein concentration was measured by Pierce BCA Protein Assay (Thermo Scientific). SDS-Page was performed using standard protocol for NuPAGE Bis-Tris Mini Gels by Thermo Fisher Scientific. Samples were combined with NuPAGE LDS Sample Buffer (4x), NuPAGE Reducing Agent (10x), and DI water. 200 mL of 1x NuPAGE MOPS Running Buffer was added to 500 μL NuPAGE antioxidant for upper chamber buffer. SDS-PAGE was run using PowerEase for 45 min on a 200 V constant. Membrane transfer was performed overnight at 17 V. Blocking was performed with 5% milk in phosphate buffer saline in Tweek 20 (PBS-T) for 1 h at room temperature, followed by overnight primary antibody incubation. Secondary antibody incubation was performed for 1 h at room temperature. The membrane was washed with PBS-T between incubations. The protein was detected using SuperSignal West PICO Plus Chemiluminescent substrate (Thermo Fisher Scientific) and was visualized by ChemiDoc Imaging Systems (BioRad Laboratories). The protein band intensity was quantified by Image Lab (v6.0.1, BioRad Laboratories).

RNA extraction and qRT-PCR
Total RNA was isolated from lung immortalized or malignant cell lines without treatment (AALE, PC9, H1650, H3255, HCC827, H1975), H1975-derived parental and OTR cells with or without AICAR treatment (0.0, 0.1, and 1 mM), or H₂O₂ treatment (0.5 and 1 mM) for 4 h using mirVana miRNA Isolation Kit (Ambion #AM1561, Invitrogen). Similarly, the lentiviral or LNA miRNA inhibitor-treated cells were processed for RNA extraction. For miRNA expression analysis, 10 ng RNA in each sample was input for consecutive reactions, including Poly(A) Tail reaction, Ligation reaction, Reverse Transcription reaction, and miR-Amp reaction using the Taqman Advanced miRNA cDNA synthesis kit (Applied Biosystems #A28007). miRNA expression levels were determined by Taqman Fast Advanced miRNA Assays (Applied Biosystems) protocol. For pre-miRNA expression analysis, 500 ng RNA in each sample was input using a high-capacity RNA-to-cDNA kit according to the manufacturer’s instructions (Applied Biosystems #4387406). Real-time PCR was performed using TaqMan probes on QuantStudio Real-Time PCR (Thermo Fisher Scientific). Taqman Advanced miRNA probes (Applied Biosystems) included the following miRNAs: hsa-miR-21-3p (Cat#477975_mir), hsa-miR-21-3p (Cat#477973_-mir), hsa-miR-423-5p (Cat#478090_mir), and hsa-miR-186-5p (Cat# 477940_mir). Taqman gene expression probes included hsa-pre-miR-21.
miRNA-seq
For microRNA sequencing (miRNA-seq) of OTR cells, the paired parental and OTR cells (treated with 20 nM osimertinib or a vehicle for 14 days) from HCC827 and PC9 cells were applied. For miRNA-seq of WZ4002-tolerant cells from an independent lab [43], the WZ4002-tolerant cells (established by culturing in 300 nM WZ4002 for 2 weeks) from PC9 were processed. For miRNA-seq of cells with a short-term response to WZ4002, the parental PC9 cells treated with 1 μM WZ4002 (WZ4002_PC9) or a vehicle for 24 h were used. The WZ4002-tolerant cells were taken out of the drug for 48 h prior to being rechallenged with WZ4002 (WZ4002_PC9_WP2) or a vehicle (vehicle_PC9_WP2) for 48 h. The total RNA samples (1 μg) were applied by LC Sciences for miRNA-seq. All RNA samples were analyzed for quality on an Agilent 2100 Bioanalyzer. The RNA samples were processed utilizing Illumina’s TruSeq small RNA sample preparation protocol for small RNA library generation (Part#15004197 Rev. F, Cat# RS-200-9002DOC). The subsequent sequencing was performed on the HiSeq 2500 platform for 1 × 50 nt single-end sequencing, and the sequencing adapter was trimmed from the raw reads. The reads were then mapped to the miBase v21 (http://www.mirbase.org/) and the human genome (GRCh37) using Bowtie [101]. The mapping results were summarized using an in-house script to estimate the number of reads mapped to each miRNA. Normalization was done using the median of the ratio of the read count to the geometric mean of read counts across samples as implemented in DESeq [102].

Transfection by LNAs in vitro
Tumor cells were plated in a completed growth medium in a six-well plate to reach 50–60% confluence. In all, 120 nM of fluorescein-labeled LNA anti-miR-21-3p (Sequence: AGCCCATCGACTGGTGTT) (Cat# 339121 YI04101754–ATAGCT) (Cat#4100689-011, Exiqon-Qiagen) or a negative control (sequence: TAACACGTCTATAAGCT) (Cat#199006-011, Exiqon-Qiagen) with PureFection (System Biosciences) were applied for transfection. The transfected cells were harvested after cultivating for 8 h (for ROS detection by flow cytometry) or 48 h (for western blot assay).

Transient transfection and dual-glo luciferase assay
PureFection (System Biosciences) was used for transient transfection. In total, 100 ng of wild-type (Genecopoeia, Hm1171862-MT06) or mutant 3′UTR reporter construct of AOSL (Genecopoeia, Hm1171862-MT06-01) was co-transfected into H1975 cells with 120 nM of LNA anti-miR-21-3p, LNA anti-miR-21-5p, or a negative control (Exiqon-Qiagen) in three–five replicates. Firefly and Renilla luciferase activities were measured 48 h post-transfection using Dual-Glo Luciferase Assay (Promega, E2940). The firefly-luminescence was normalized to renilla luminescence as an internal control for transfection efficiency, miR-21-3p-binding site GGTGTT was substituted with GCACAT in mutated AOSL.

Lentiviral infection
For lentiviral overexpression (Lenti miRa-GFP-hsa-miR-21-5p, Cat# mh15276) or knockdown of miR-21-3p (Lenti miRa-Off-hsa-miR-21-5p virus, Cat# mh35326), cells (HCC827 and H1975) at 70% confluence were transduced with the lentiviral particles labeled with green fluorescence protein (GFP) (Applied Biological Material Inc, ABM) for 48 h in the presence of 1:100 Viralplus transduction enhacer (ABM) and 8 μg mL−1 polybrene (Sigma). The Lenti III-miR control virus (Cat# M002) and the Lenti III-miR-Off control virus (Cat# M008) serve as negative controls for miRNA overexpression and knockdown, respectively. Two days after infection, puromycin was added to the media to 0.5 μg mL−1, and cell populations were selected for 1–2 weeks.

Metabolite extraction
The metabolomics samples from paired OTR and parental cells, OTR cells with miR-21 knockdown and scrambled control from H1975, and MIR21 knockout and scrambled control were prepared according to a previous method [103]. Briefly, the cells and the tissues were incubated with 80% methanol at −80 °C for 15 min. The cell and tissue lysate/methanol mixture was centrifuged at 4500 × g at 4 °C for 15 min three times in a cold room. The supernatants were dried entirely by SpeedVac and were further processed for liquid chromatography-mass spectrometry (LC-MS) analysis.

ROS assay by flow cytometry
For comparisons of ROS levels between H1975 parental and OTR cells, as well as OTR cells treated with a scrambled control, miRNA inhibitors labeled with fluorescein against miR-21-5p and miR-21-3p 8 h post-transfection, the cells above (1 × 10^6 cells/250 μl/well) were seeded in a 24-well plate (Falcon). After 24 h, cells were treated for 4 h with 250 μL of vehicle, AICAR (1 mM), osimertinib (1 μM), or a combo of AICAR (1 mM) and osimertinib (1 μM) and then were trypsinized and collected. For longitudinal measurement of ROS levels, H1975 parental cells (12 × 10^6 cells/250 μl/well) were seeded in a 24-well plate (Falcon). After 24 h, cells were treated with 250 μl of AICAR (1 mM) and osimertinib (1 μM) for 0, 2, 4, 6, 8, and 24 h before trypsinization and collection. Reactive oxygen species (superoxide and hydroxyl radical) were measured with deep red fluorescence (Abcam, Cat# ab186029). The single-cell suspension was incubated for 45 min at 37 °C with deep red dye diluted to 1× in assay buffer for ROS detection. After incubation, the dye was removed, and cells were washed once with PBS and resuspended in phenol red-free DMEM ( Gibco, Cat# 2187289) supplemented with 10% FBS and 1% penicillin-streptomycin. The fluorescence was measured with a flow cytometer using CytoFLEX (Beckman Coulter) via APC channel (Ex/Em:633/660). In all, 10,000 independent events were analyzed with CytExpert software (Beckman Coulter) from the total live cells (OTR and parental) and the total GFP− cells (OTR treated with the LNA inhibitors labeled with fluorescein).

Statistical analyses
All experiments were performed in two to five biological replicates and independently reproduced as indicated in figure legends. Investigators were blinded to the group allocation during the procedure and data analysis. Data are presented as the means ± SEM. Unless otherwise stated, statistical significance was determined by a Student’s two-tailed t-test by GraphPad Prism (v8.4.3). P < 0.05 was considered statistically significant. Two-tailed t-test with Welch’s correction was applied for two samples with unequal variances. For three and more normally distributed samples with equal variances, one-way ANOVA was used for multiple comparisons. For three and more normally distributed samples with unequal variances, Brown–Forsythe and Welch ANOVA was used for multiple comparisons. For three and more samples that are not normally distributed, the Kruskal–Wallis test was used for multiple comparisons. For three and more matched samples, RM one-way ANOVA was used for multiple comparisons. Pearson correlation coefficient was used for correlation analysis between AOSL and miRNA-21 expression in lung tumor tissues from patients from three independent datasets in the Lung Cancer Explorer web portal. Significance for Bliss synergy analysis was calculated via a one-sample t-test.

DATA AVAILABILITY
Data from this study have been deposited in the Gene Expression Omnibus (GEO) databases under the following accession: GSE103352 (miRNA-seq). The results shown in this manuscript were partially based upon data generated by the Lung Cancer Explorer portal. https://ics.biopcs.wmed.edu/lungcancer/. The experimentally validated miRNA–gene interactions were collected from the Tarbase (v8): https://carolina.imis.athena-innovation.gr/diana_tools/web/index.php?t=tabbasev8%2Findex. The genetic mutation status was confirmed by the Cansar portal (v3.0 beta)
REFERENCES

1. Win MN, Liang JC, Smolke CD. Frameworks for programming biological function through RNA parts and devices. Chem Biol. 2009;16:298–310.

2. Becker S, Feldmann J, Wiedemann S, Okamura H, Schneider C, Iwan K, et al. Uniﬁed prebiotically plausible synthesis of pyrimidine and purine RNA nucleotides. Science. 2019;365:67–82.

3. Zoller N, Purine and pyrimidine metabolism. Proc Nutr Soc. 1982;41:329–42.

4. Spiegel EK, Colman RF, Patterson D. Adenylsuccinate lyase deﬁciency. Mol Genet Metab. 2006;89:19–31.

5. Liu C, Knudsen GM, Pedley AM, He J, Johnson JL, Yaron TM, et al. Mapping post-translational modiﬁcations of de novo purine biosynthetic enzymes: implications for pathway regulation. J Proteome Res. 2018;17:2078–87.

6. Ben-Sahra L, Hoxjah G, Ricoult SJH, Asara JM, Manning BD. mTORC1 induces purine synthesis through control of the mitochondrial tetrahydrofolate cycle. Science. 2016;351:728–33.

7. Helms M. Post-transcriptional nucleotide modiﬁcation and alternative folding of RNA. Nucleic Acids Res. 2006;34:721–33.

8. Valencia-Sanchez MA, Liu J, Hannon GJ, Parker R. Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev. 2006;20:515–24.

9. Anastasiadou E, Jacobs LS, Slack FJ. Non-coding RNA networks in cancer. Nat Rev Cancer. 2018;18:15–8.

10. Slack FJ, Chinnaiyan AM. The role of non-coding RNAs in oncology. Cell. 2019;179:1033–55.

11. Citrin KM, Fernandez-Hernando C, Suarez Y. MicroRNA regulation of cholesterol metabolism. Nat Rev. 2021;1495:55–77.

12. Boehm M, Slack FJ. MicroRNA control of lifespan and metabolism. Cell Cycle. 2006;5:837–40.

13. Puissegur MP, Masure NM, Bertero T, Pradelli L, Grosso S, Robbe-Sermesant K, et al. miR-210 is overexpressed in late stages of lung cancer and mediates pseudohypoxia. Cell Death Differ. 2011;18:465–78.

14. Zhang WC, Wells JM, Chow KH, Huang H, Yuan M, Saxena T, et al. miR-147b-mediated TCA cycle dysfunction and pseudohypoxia initiate drug tolerance to EGFR inhibitors in lung adenocarcinoma. Nat Metab. 2019;1:460–74.

15. Lei W, Kang W, Nan Y, Lei Z, Zhongdong L, Demin L, et al. The downregulation of miR-20C promotes lactate dehydrogenase A expression and non-small cell lung cancer progression. Oncol Res. 2018;26:1015–22.

16. Singh A, Happel C, Manna SK, Acquah-Mensah G, Carrero J, Kumar S, et al. Transcription factor NRF2 regulates miR-1 and miR-206 to drive tumorigenesis. J Clin Invest. 2013;123:2921–34.

17. Nagarajan MB, Tentori AM, Zhang WC, Slack FJ, Doyle PS. Spatially resolved and multiplexed MicroRNA quantiﬁcation from tissue using nanoliter well arrays. NanoMach. 2020;5:26.

18. Zhang WC, Wells JM, Chow KH, Huang H, Yuan M, Saxena T, et al. miR-147b-mediated TCA cycle dysfunction and pseudohypoxia initiate drug tolerance to EGFR inhibitors in lung adenocarcinoma. Nat Metab. 2019;1:460–74.

19. Lei W, Kang W, Nan Y, Lei Z, Zhongdong L, Demin L, et al. The downregulation of miR-20c promotes lactate dehydrogenase A expression and non-small cell lung cancer progression. Oncol Res. 2018;26:1015–22.

20. Singh A, Happel C, Manna SK, Acquah-Mensah G, Carrero J, Kumar S, et al. Transcription factor NRF2 regulates miR-1 and miR-206 to drive tumorigenesis. J Clin Invest. 2013;123:2921–34.

21. Nagarajan MB, Tentori AM, Zhang WC, Slack FJ, Doyle PS. Spatially resolved and multiplexed MicroRNA quantification from tissue using nanoliter well arrays. NanoMach. 2020;5:26.

22. Zhang WC, Wells JM, Chow KH, Huang H, Yuan M, Saxena T, et al. miR-147b-mediated TCA cycle dysfunction and pseudohypoxia initiate drug tolerance to EGFR inhibitors in lung adenocarcinoma. Nat Metab. 2019;1:460–74.

23. Lei W, Kang W, Nan Y, Lei Z, Zhongdong L, Demin L, et al. The downregulation of miR-20c promotes lactate dehydrogenase A expression and non-small cell lung cancer progression. Oncol Res. 2018;26:1015–22.

24. Singh A, Happel C, Manna SK, Acquah-Mensah G, Carrero J, Kumar S, et al. Transcription factor NRF2 regulates miR-1 and miR-206 to drive tumorigenesis. J Clin Invest. 2013;123:2921–34.

25. Nagarajan MB, Tentori AM, Zhang WC, Slack FJ, Doyle PS. Nonfouling, encoded hydrogel microparticles for multiplex microRNA proﬁling directly from formalin-ﬁxed, parafﬁn-embedded tissue. Anal Chem. 2019;90:10279–85.

26. Adams BD, Parsons C, Walker L, Zhang WC, Slack FJ. Targeting noncoding RNAs in disease. J Clin Investig. 2017;127:761–71.

27. Nagarajan MB, Tentori AM, Zhang WC, Slack FJ, Doyle PS. A high-throughput small molecule screen identiﬁes ouabain as synergistic with miR-34a in killing lung cancer cells. iScience. 2020;23:100788.

28. Gilles ME, Hao L, Huang L, Rupaimoole R, Lopez-Casas PP, Pulver E, et al. Personalized RNA medicine for pancreatic cancer. Clin Cancer Res. 2018;24:1734–47.

29. Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Disc. 2017;16:202–33.

30. Zhang WC, Slack FJ. ADARs edit microRNAs to promote leukemic stem cell activity. Cell Stem Cell. 2016;19:141–2.

31. Zoller N, Purine and pyrimidine metabolism. Proc Nutr Soc. 1982;41:329–42.

32. Bibb M, Kroissmayr R, Lichtenberger BM, Natarajan A, Hecking M, Holmman M. The epidermal growth factor receptor: from development to tumorigenesis. Differentiation. 2007;75:770–87.

33. Barber TD, Vogelstein B, Kinzler KW, Velculescu VE. Somatic mutations of EGFR in colorectal cancers and glioblastomas. N. Engl J Med. 2004;351:2883.

34. Linardou H, Dababneh UJ, Bafaloulkos D, Kosmidis P, Murray S. Somatic EGFR mutations and efﬁcacy of tyrosine kinase inhibitors in NSCLC. Nat Rev Clin Oncol. 2009;6:352–66.

35. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:1497–500.

36. Zhang WC, Slack FJ. MicroRNA-21 mediates resistance to EGFR tyrosine kinase inhibitors in lung cancer. J Thorac Oncol. 2016;11:1798–1809.

37. Sibilia M, Kroissmayr R, Lichtenberger BM, Natarajan A, Hecking M, Holmman M. The epidermal growth factor receptor: from development to tumorigenesis. Differentiation. 2007;75:770–87.

38. Ge Y, Zhang L, Nikolova M, Reva B, Fuchs E. Strand-speciﬁc microRNA expression modulates gene expression in vivo. Cell. 2004;115:283–92.

39. Shan sourcing directly from formalin-ﬁxed, parafﬁn-embedded tissue. Anal Chem. 2019;90:10279–85.
mutated lung cancer cell lines. We thank Alka Mehta (UCF) and Jeremiah Oyer (UCF) for technical support on reporter assay and flow cytometry assay, respectively. We apologize to all researchers whose work could not be cited due to reference limitations.

AUTHOR CONTRIBUTIONS
WCZ and FJS designed the experiments and wrote the manuscript with input from all authors. WCZ established drug-tolerant persister cell lines, miRNA infection and transfection, correlation analysis and metabolomics analysis (Figs. 1A–Q, 2A–D, H, 3A–C, 5A-G, Supplementary Figs. 2, 3, and Supplementary Tables 1–10). NS performed dual-luciferase reporter assay, western blot assay, and qRT-PCR experiments (Figs. 1E–G, K, N, 3C, 4A, B, G, H, and Supplementary Figs. 6–10, 15, 16). FA performed small molecule treatment, dual-luciferase reporter assay, ROS assay, and timepoint experiments (Figs. 1H, O, 2E, F, 3B, 4A, C–G, and Supplementary Figs. 4, 11–14). CM performed miRNA expression analysis and target prediction (Figs. 1E–G, K, N–O, 3H, and Supplementary Figs. 3, 5, 13, 14). LS performed the western blot assay and analysis (Fig. 3D–F, 1–M, B, H, and Supplementary Figs. 5, 16). PJAC performed the metabolomics experiment (Figs. 2A–D and 5C and Supplementary Tables 3–5), and ANH provided RNA samples from PC9 parental and drug-tolerant cells (Supplementary Fig. 1).

COMPETING INTERESTS
ANH has received research support from Novartis, Relay Therapeutics, Pfizer, Roche/Genentech, Amgen, Eli Lilly, Blueprint Medicines, Nuvonel, Scorpion Therapeutics, and BridgeBio. ANH has served as a paid consultant for Nuvonel, EngineBio and Tolermo Therapeutics. The remaining authors declare no competing interests.

ADDITIONAL INFORMATION
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41417-022-00504-y.

Correspondence and requests for materials should be addressed to Wen Cai Zhang or Frank J. Slack.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022, corrected publication 2022